The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
MD · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
| Measure | MD | QURE | CNMD | INIS |
|---|---|---|---|---|
| Moat Score (0–100) | 39 (highest) | 39 (highest) | 39 (highest) | 39 (highest) |
| Methodology version | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 |
| Business trend | 57 | 15 | 56 | 61 (highest) |
| Pricing power | — | 96 (highest) | 92 | 84 |
| Returns on capital | 8 (highest) | 7 | 0 | 0 |
| Balance-sheet safety | 51 | 55 (highest) | 3 | 28 |
| Capital discipline | 40 | 24 | 45 (highest) | 24 |
| Price vs. high estimate | 190% above high estimate | No price data | 26% below high estimate (largest discount to high estimate) | No price data |
| Market cap | $2.1B | $2.4B | $1.3B | $31.6M |
| Moat tier | No moat | No moat | No moat | No moat |
| Filings as of | FY2025 | FY2025 | FY2025 | FY2025 |